Immunotherapy is Fastest Growing Segment Fueling the Growth of Wilms Tumor Protein Market

 

WILMS TUMOR PROTEIN MARKET


The global Wilms Tumor Protein Market is estimated to be valued at US$ 2.92 Bn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:
Wilms tumor protein also known as WT1 is a tumor suppressor gene that plays a vital role in regulation of cell growth and differentiation during embryonic development. It is commonly expressed in leukemia and solid tumor cancers. Therapies targeting WT1 play a crucial role in treatment of cancers.

Market key trends:
Immunotherapy targeting WT1 has emerged as one of the promising and fastest growing segments in the market. Several antibodies and therapeutic vaccines targeting WT1 are being investigated and developed to boost body's own immune system to fight against cancer cells. For instance, WT1 peptide vaccines are being studied for treatment of acute myeloid leukemia and multiple myeloma. Additionally, WT1 targeted chimeric antigen receptor T-cell therapies are under research for treatment of leukemias.
Segment Analysis
The global Wilms Tumor Protein market is segmented based on technology, end-user and region. Based on technology, the market is segmented into immunohistochemistry, western blot, immunofluorescence and others. The immunohistochemistry segment dominates the market due to its widespread adoption by research institutes and hospitals for cancer diagnosis. Based on end-user, the market is segmented into hospitals, diagnostic centers, research institutes and others. The research institutes segment dominates due to high focus on research activities for development of novel drugs for cancer treatment.

Key Takeaways
The global Wilms Tumor Protein market size is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing incidences of cancer globally. The market size for 2023 is US$ 2.92 Bn.

Regional analysis
North America dominates the global Wilms Tumor Protein market due to presence of advanced healthcare infrastructure and high adoption of advanced diagnostic techniques for cancer diagnosis in the region. Asia Pacific exhibits the fastest growth over the forecast period due to increasing healthcare expenditure, rising incidences of cancer and growing research activities in countries like China and India.

Key players
Key players operating in the Wilms Tumor Protein market are Abcam plc, Thermo Fisher Scientific, Inc., Santa Cruz Biotechnology, Inc., Novus Biologicals, LLC, R&D Systems, Inc. (a subsidiary of Bio-Techne Corporation), OriGene Technologies, Inc., Cell Signaling Technology, Inc., Merck KGaA, BioLegend, Inc., Genetex, Inc. (a subsidiary of Novus Biologicals, LLC), Agilent Technologies, Inc., Proteintech Group, Inc., Sino Biological Inc., Boster Biological Technology, Fitzgerald Industries International

Comments

Popular posts from this blog

Rising Adoption Of Non-Invasive Screening Techniques Is Anticipated To Open Up New Avenues For The Leukemia Screening Market

GCC Air Purifier Market Estimated to Witness High Growth Owing to Rising Pollution Levels

Global Naphthenic Base Oil Market Estimated to Witness High Growth Owing to Rising Adoption in Various End-Use Industries